First PREMIER Bank’s SAB Biotherapeutics SABS Stock Holding History

First PREMIER Bank’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$60K	Hold	18,986	–	–	0.01%	239
2026 Q2	$74K	Hold	18,986	–	–	0.01%	219
2026 Q1	$73K	Hold	18,986	–	–	0.02%	210
2025 Q4	$71K	Hold	18,986	–	–	0.02%	208
2025 Q3	$38K	Hold	18,986	–	–	0.01%	248
2025 Q2	$33K	Hold	18,986	–	–	0.01%	249
2025 Q1	$26K	Hold	18,986	–	–	0.01%	260
2024 Q4	$72K	Sell	18,986 -400	-2%	-$1.31K	0.02%	208
2024 Q3	$52K	Hold	19,386	–	–	0.01%	231
2024 Q2	$60K	Buy	+19,386	New	+$71.1K	0.02%	201
2024 Q1	–	Sell	-80,754	Closed	-$555K	–	509
2023 Q4	$555K	Hold	80,754	–	–	0.16%	101
2023 Q3	$509K	Hold	80,754	–	–	0.16%	100
2023 Q2	$670K	Hold	80,754	–	–	0.19%	90
2023 Q1	$355K	Hold	80,754	–	–	0.1%	116
2022 Q4	$476K	Hold	80,754	–	–	0.14%	95
2022 Q3	$566K	Buy	80,754 +15,510	+24%	+$154K	0.18%	90
2022 Q2	$946K	Buy	+65,244	New	+$1.37M	0.28%	76
2022 Q1	–	Sell	-83,256	Closed	-$6.5M	–	383
2021 Q4	$6.5M	Buy	+83,256	New	+$7.81M	1.68%	16

Other funds holding SABS

HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

First PREMIER Bank's SABS Position: Q3 2026 in Review

First PREMIER Bank held its SAB Biotherapeutics (SABS) position steady in Q3 2026 at 18,986 shares worth $60K. The position accounts for 0.01% of the portfolio, ranked #239.

First PREMIER Bank first reported a position in SABS in Q4 2021 and has held it in 18 quarters since. The position peaked at $6.5M in Q4 2021. 6 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

First PREMIER Bank held 18,986 shares of SAB Biotherapeutics worth $60K as of Q3 2026.
First PREMIER Bank left its SAB Biotherapeutics share count unchanged in Q3 2026.
SAB Biotherapeutics made up 0.01% of First PREMIER Bank's portfolio in Q3 2026, its #239 holding.
First PREMIER Bank first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 18 quarters since.
First PREMIER Bank's SAB Biotherapeutics position peaked at $6.5M in Q4 2021.
6 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on First PREMIER Bank's 13F filing for Q3 2026, filed 13 Oct 2026.